StockNews.AI
ABUS
StockNews.AI
118 days

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

1. Five abstracts accepted at EASL Congress for hepatitis B therapies. 2. Imdusiran shows promising functional cure rates in chronic hepatitis B patients. 3. AB-101 demonstrates safety and pharmacokinetics in healthy subjects. 4. Posters presenting high-impact findings on HBV treatment strategies. 5. Ongoing clinical trials may affect future treatment direction and approval.

11m saved
Insight
Article

FAQ

Why Bullish?

Positive data from abstracts, particularly regarding imdusiran, can drive investor confidence, mirroring past events where data disclosures resulted in price spikes.

How important is it?

Recent positive developments and confirmed data presentations enhance ABUS's market visibility and growth potential, vital for a developmental biotech.

Why Short Term?

Upcoming conference presentations may cause immediate price movements based on investor sentiment around presented data.

Related Companies

GILDMRNAVRTX
Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7 - 10, 2025 in Amsterdam, Netherlands. The following abstracts will be presented as posters in the Viral Hepatitis B and D: New Therapies, Unapproved Therapies or Strategies session on May 8, 2025, from 8:30 am – 5:00 pm CET. Abstract Number: 1768Title: IM-PROVE I: characterization of chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after completion of imdusiran plus short courses of pegylated interferon alfa-2a (IFN) and discontinuation of nucleos(t)ide analogue (NA) therapyPresenter: Prof. Man-Fung YuenPresentation Date: May 8, 2025Key Findings: Within this small group of subjects who achieved functional cure or HBV DNA

Related News